Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir
Dig Dis Sci
.
2015 Jan;60(1):272-4.
doi: 10.1007/s10620-014-3374-1.
Epub 2014 Oct 5.
Authors
Perry H Dubin
1
,
Seth N Sclair
,
Rene Rico
,
Amelia K Boehme
,
Emerson Y Chen
,
Paul Martin
,
William M Lee
Affiliation
1
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
PMID:
25283376
PMCID:
PMC4604568
DOI:
10.1007/s10620-014-3374-1
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents / therapeutic use*
Female
Hepatitis C, Chronic / drug therapy*
Humans
Male
Oligopeptides / therapeutic use*
Proline / analogs & derivatives*
Substances
Antiviral Agents
Oligopeptides
Proline
Grants and funding
T32 NS007153/NS/NINDS NIH HHS/United States